Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10448822" target="_blank" >RIV/00669806:_____/22:10448822 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00843989:_____/22:E0109845 RIV/65269705:_____/22:00076456 RIV/00064173:_____/22:43924109 RIV/00098892:_____/22:10157300 a 7 dalších
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=03C.N5eihU" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=03C.N5eihU</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/biomedicines10102535" target="_blank" >10.3390/biomedicines10102535</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Popis výsledku v původním jazyce
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients' data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bonemarrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0-NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and >=3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4-28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3-67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.
Název v anglickém jazyce
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Popis výsledku anglicky
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients' data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bonemarrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0-NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and >=3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4-28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3-67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomedicines
ISSN
2227-9059
e-ISSN
2227-9059
Svazek periodika
10
Číslo periodika v rámci svazku
10
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
15
Strana od-do
2535
Kód UT WoS článku
000872196600001
EID výsledku v databázi Scopus
2-s2.0-85140620403